Temple unveils BrainFlow wearable to monitor brain blood flow

Deepinder Goyal-backed Temple has introduced BrainFlow, a wearable designed to monitor brain blood flow. The company said the system was validated against TD-NIRS in a study involving 60 participants.

— Source publishedMon, 28 Sept, 2026, 15:34 IST·First seen Mon, 28 Sept, 2026, 17:10 IST·Source NDTV Profit

The brand move

Temple unveiled BrainFlow, a wearable brain blood-flow monitoring system validated against TD-NIRS in a study involving 60 participants.

The numbers

  • 20%
  • 60

Why it matters for the brand

Temple’s BrainFlow launch expands its consumer-tech brand into health monitoring, creating a premium wellness category opportunity but requiring clear in-store education and trust-building around clinical validation.

What to track next

  • Release of full study methodology, peer review, confidence intervals and comparison results versus TD-NIRS.
  • Device price, subscription model, launch geography and early customer-review evidence on comfort, battery life and signal consistency.
  • Whether Temple labels BrainFlow as a wellness device or pursues medical-device clearance.
  • Announcements of hospital, university, sports-team, insurer or employer-wellness pilots.
  • Evidence that readings correlate with usable outcomes such as recovery, migraine, concussion, sleep quality or cognitive-fatigue signals.

The counter-case

BrainFlow may be a technically interesting sensor rather than a durable consumer product. Validation against TD-NIRS in only 60 participants does not establish clinical accuracy, usefulness across diverse users or conditions, or that monitoring blood-flow signals leads to better health outcomes. The product could face high false-positive/false-reassurance risk, unclear regulatory positioning, privacy concerns around sensitive neurological data, and weak repeat-use behavior if consumers do not understand what to do with the readings.